Document Detail


Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
MedLine Citation:
PMID:  22890557     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Polo-like kinase 1 (Plk1) is a mitotic serine/threonine kinase and its kinase activity is closely interrelated to cell cycle progression, various types of cancer development and often correlates with poor prognosis. Thus, it is of prime importance to characterize the phenotypes of Plk1 inhibition in cells for drug development and clinical application. Here, we report a novel kinase inhibitory chemical, CBB2001, which specifically inhibited Plk1 kinase activity in vitro with an IC(50) of 0.39 μM. In cervical carcinoma HeLa cells, we found that treatment of CBB2001 caused mitotic cell cycle arrest (EC(50)=0.72 μM) and induction of 'polo' cells (EC(50)=0.32 μM). Interestingly, the cell cycle arrest induced by CBB2001 was associated with accumulation of Plk1 (EC(50)=0.61 μM) and Geminin (EC(50)=0.43 μM) proteins, but distinct from the phenotypes induced by Aurora kinase inhibitors. The inhibitory effects of CBB2001 were phenocopied by RNA interferences of Plk1. We also confirmed the cell cycle inhibitory effects of CBB2001 in other cancer cells. Moreover, CBB2001 inhibited the growth of HeLa cells with an IC(50) of 0.85 μM in MTT assays, which is better than that of reported Plk1 inhibitory chemicals ON01910 (IC(50)=6.46 μM) and LFM-A13 (IC(50)=37.36 μM). CBB2001 also inhibited mouse xenograft tumor growth. Furthermore, CBB2001 inhibited mitotic exit and delayed degradation of APC/C substrates, Geminin, Cyclin B1 and Aurora A. These specific phenotypes may serve as specific features for Plk1 inhibition and for Plk1-based clinic trials.Laboratory Investigation advance online publication, 13 August 2012; doi:10.1038/labinvest.2012.114.
Authors:
Rongfeng Lan; Guimiao Lin; Feng Yin; Jun Xu; Xiaoming Zhang; Jing Wang; Yanchao Wang; Jianxian Gong; Yuan-Hua Ding; Zhen Yang; Fei Lu; Hui Zhang
Related Documents :
17346177 - Purine metabolism in mycobacterium tuberculosis as a target for drug development.
20625797 - Globular adiponectin regulates energy homeostasis through amp-activated protein kinase-...
17928927 - High-level expression of functional tumor suppressor lkb1 in escherichia coli.
11546797 - Stimulation of glucose transport by amp-activated protein kinase via activation of p38 ...
19028457 - Targeting ret for thyroid cancer therapy.
22309147 - Calcium/calmodulin inhibition of the arabidopsis brassinosteroid-insensitive 1 receptor...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-13
Journal Detail:
Title:  Laboratory investigation; a journal of technical methods and pathology     Volume:  -     ISSN:  1530-0307     ISO Abbreviation:  Lab. Invest.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376617     Medline TA:  Lab Invest     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor ...
Next Document:  Atypical cry acoustics in 6-month-old infants at risk for autism spectrum disorder.